Injectable Drug Delivery Market to Hit $1.03 Trillion by 2030: Strategic Opportunities for C-Level Executives in Biopharma & MedTech
The injectable drug delivery market is driven by the rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, alongside an increasing global demand for biologics.
The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$690.23 billion in 2025 and an impressive US$1,034.78 billion by 2030. The injectable drug delivery market is driven by the rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, alongside an increasing global demand for biologics. Developed markets like the US, Germany, and Japan continue to adopt advanced delivery technologies, supported by strong healthcare infrastructure and patient preference for convenient, self-administered therapies. In emerging markets such as India, Brazil, and China, market growth is accelerated by improved healthcare access and government-backed immunization and chronic disease management programs.
Key market trends include the increasing adoption of wearable injectors, autoinjectors, and needle-free systems. This shift is largely driven by a growing emphasis on patient compliance and home-based treatment options. Additionally, the move towards personalized medicine and combination therapies encourages device manufacturers to create tailored solutions for complex drug regimens.
Recent developments in this market include the introduction of smart injectors that feature connectivity capabilities, the expansion of large-volume subcutaneous delivery systems, and partnerships between pharmaceutical companies and device developers aimed at creating biologics-compatible delivery platforms. Many companies also invest in sustainable and reusable injection systems, especially in Europe, to comply with environmental regulations.
Overall, the market is evolving rapidly, with a strong focus on innovation aimed at enhancing safety, usability, and therapeutic efficacy. This positions injectable delivery systems as a crucial element in modern disease management strategies worldwide.
Browse in-depth TOC on " Injectable Drug Delivery Market"
1000 - Tables
120 - Figures
650 - Pages
By Based on products, the formulations segment accounted for the largest market share in 2024, primarily due to the increased use of biologics. The rising prevalence of chronic diseases such as cancer, HIV, and obesity further fuels the growth of this market. The parenteral route of drug administration is considered ideal for biologics, as it enhances the bioavailability of therapeutic agents and maintains their stability. Additionally, a strong focus on research and development for targeted and controlled drug delivery drives market expansion. Long-acting and sustained-release formulations reduce dosing frequency, improving patient compliance. Innovations in injectable drug formulations, including the use of nanoparticles, micelles, and liposomes for targeted drug delivery, also contribute to market growth.
By formulation packaging, the ampoules segment is projected to grow at the highest CAGR within the formulation packaging sector. This growth can be attributed to the numerous advantages ampoules offer over other packaging options, such as vials. Ampoules are typically designed for single use, significantly reducing the risk of cross-contamination and ensuring accurate therapeutic product dosages. Additionally, they are more cost-effective than prefilled syringes, cartridge-based packaging, and vials. Glass ampoules are compatible with a wide range of therapeutic agents, including biologics, and help maintain their stability. Moreover, ampoules provide a longer shelf life for drugs and are easy to store.
By therapeutic application, the rapid growth of the obesity market segment is driven by the sedentary lifestyle of people worldwide. The high consumption of over-processed foods and various environmental factors significantly contribute to this trend. Additionally, genetic predisposition plays a role in the prevalence of this chronic condition.
Recent advancements in self-administration devices, such as autoinjectors and wearable technology, have made it easier for individuals to administer medication, especially in emergency situations. These devices provide options for at-home care, improving patient compliance. Furthermore, long-acting injectable formulations reduce the frequency of required medication dosages.
By site of administration, the dermal segment accounted for the largest market share in 2024. This segment encompasses both intradermal and subcutaneous routes of administration. The significant market share can be attributed to the ease of dermal-based administration, which is less invasive than intravenous routes. Dermal administration is also less painful and is typically preferred by patients who require frequent dosing for chronic conditions.
The subcutaneous route is particularly well-suited for self-administration devices, such as autoinjectors and pen injectors. In addition, needle-free injectors and microneedle devices are being developed for intradermal administration, which enhances patient compliance. Dermal-based injections are appropriate for a wide range of therapeutic products, including biologics, insulin, and vaccines.
By geography, the APAC region is projected to experience the highest CAGR globally during the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions in the region. The aging population further contributes to this trend. Significant investments in the healthcare sector are being made in countries like China, India, and Southeast Asia, which facilitate the development of hospitals, clinics, and healthcare facilities. Supportive government policies and regulations also play a vital role in this growth.
Prominent players in the injectable drug delivery market are Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), Baxter (US), B. Braun SE (Germany), and Terumo Corporation (Japan).
Cardinal Health (US):
Cardinal Health (US) is a global supplier of healthcare products and services in over 30 countries. The company has two main segments: Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution. It provides services to hospitals, pharmacies, laboratories, and home-care settings. In addition to drug distribution, the pharmaceutical division offers specialized services such as logistics management, nuclear pharmacy, and specialty pharmacy. The Healthcare division offers a wide range of products, including safety syringes (under the Magellan and Monoject brands), laboratory supplies, and anesthesia devices. Cardinal Health's OptiFreight Logistics service manages over 22 million shipments annually, optimizing supply chain performance. The company is dedicated to innovation, operational excellence, and improving patient care outcomes through its extensive network and advanced analytical capabilities.
BD (US):
BD (US) is a global company that supplies medical devices, diagnostic equipment, and interventional treatments in over 190 countries. The organization has three main business divisions: Interventional, Life Sciences, and Medical. The Medical division focuses on drug management and delivery systems, including items like IV catheters, syringes, and needles. The Interventional division addresses critical care, urology, and surgical needs, while the Life Sciences division specializes in diagnostics and biosciences. BD is also well-known for its commitment to innovation and has several subsidiaries in Germany, Canada, and the US. Due to its advancements in patient care and contributions to health technology, Fortune ranked the company among the top 25% of the most innovative US companies in 2025.
Johnson & Johnson Services, Inc. (US):
Johnson & Johnson Services, Inc. (US) is a major healthcare company that operates through two main business segments: MedTech and Innovative Medicine. The Innovative Medicine segment offers treatments for infectious diseases, immunology, oncology, and various other conditions, distributing products through wholesalers, hospitals, and retailers. Key injectable drugs in this segment include REMICADE, SIMPONI, STELARA, TREMFYA, and DARZALEX, with the latter generating approximately USD 3 billion in quarterly sales. The company operates through more than 265 subsidiaries, such as Janssen Pharmaceuticals and Actelion Pharmaceuticals, and has a presence in over 60 countries.
F. Hoffmann-La Roche Ltd. (Switzerland)
F. Hoffmann-La Roche Ltd. (Switzerland) is a leading biotech company specializing in in vitro diagnostics and pharmaceutical products for rare diseases, immunology, ophthalmology, and cancer. Its key injectable products include Hemlibra, Ocrevus, Phesgo, and Vabysmo. Roche collaborates with over 250 global partners and conducts pharmaceutical research and development through its subsidiaries, Genentech (US) and Chugai (Japan). The company operates in over 150 countries, partnering with organizations such as Spark Therapeutics and Roche Diagnostics Corporation.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
8 hours ago
- CTV News
Sask. Virtual Health Hub launches new projects
WATCH: A born in Saskatchewan idea to transform access to healthcare is adding two new partners to its team. Members of the provincial and federal government, healthcare providers and First Nation leaders gathered at the Virtual Health Hub in Saskatoon on Friday to celebrate a milestone. 'Today we are announcing that Virtual Health Hub is joining CAN Health Network in launching two new commercialization projects with two leading Canadian Technology companies.' The partnership with CAN Health Network will allow improved access, equity and health outcomes for northern and Indigenous populations through collaboration and technology. Saskatchewan based Luxsonic and its Virtual Imaging Platform designed for radiologists to remotely view and interpret diagnostic imaging to support faster diagnoses. 'These projects give companies like ours the opportunity to prove our technology in real-world settings, build trust with healthcare providers and accelerate adoption across Canada,' said Mike Wesolowski, CEO and founder of Luxsonic. It's the company's second project with CAN Health Network. The other company added through this partnership is Nova Scotia based Virtual Hallway. The software enables physicians to consult with specialists for advice, ensuring patients get the right care faster. The company says with so many Saskatchewan residents living in rural areas but nearly all specialists living in cities, it can be hard on families and healthcare providers. 'Too often, those providers are left without timely input from a specialist,' said Dr. Luke Napier, chief medical officer at Virtual Hallway. 'And patients face long delays or long travel, or both. Virtual Hallway was built to change that. Our goals are simple and measurable, reduce unnecessary referrals and transfers, increase confidence in rural clinical decision making, and support the providers who are already doing so much.' The director of Virtual Health Hub says improvements in AI, telecommunications and robotics have allowed this shift toward a virtual delivery of healthcare. 'Since the pandemic, both the provider and the patient, that virtual care is a way of delivering healthcare,' said Dr. Ivar Mendez, director of Virtual Health Hub. 'And what I'm particularly proud of is that we are the leadership in the country, here in Saskatchewan. And Saskatchewan is the ideal place to scale up this technology.' A temporary hub location in downtown Saskatoon will be replaced by a permanent one on Whitecap Dakota Nation. 'There will be another announcement coming to announce the construction phase of the Virtual Health Hub, because that's going to be the next phase that's happening,' said Chief Darcy Bear, Whitecap Dakota Nation. 'It's not just about Indigenous healthcare, it is all about healthcare for all of Saskatchewan residents.' Bear says the new Virtual Health Hub is expected to be complete in early 2027.
CBC
9 hours ago
- CBC
Winnipeg couple leaves encampment for drug-free supportive housing
Social Sharing A homeless Winnipeg couple began a new chapter on Friday, moving into transitional housing with hopes of turning a page toward long-term addictions recovery. Anna Moar and Kadin McCron lost their apartment a couple of months ago due to a relapse following more than four years of sobriety, they said. Since then, they have been bouncing around from encampment to encampment, eventually settling on a relatively private riverbank in Winnipeg's Wolseley neighbourhood. "Our goal is to try to get as far away from the drugs and the drug users as possible, so that way we can battle ourselves through the addiction and battle ourselves through our problems and try and make a change," said McCron. He said it was at the riverbank where they connected with someone on July 25 who contacted St. Boniface Street Links, an outreach organization that helps homeless people and people with addictions. By the end of that day, the organization had come to meet them and helped them move to its 24/7 safe space on St. Mary's Road. "I'm still actually bamboozled about it," said McCron, 30. On Friday, the pair moved into the organization's building on Fountain Street, a drug-free transitional housing complex in the Centennial neighbourhood that provides residents around-the-clock support and includes 24/7 security. "I'm surprised it happened so fast. I wasn't expecting it," said Moar, 33. The couple's move comes at a time when they're both eager to leave a chaotic life behind and stay sober, with Moar also needing additional medical care. She's awaiting surgery for a broken hip and gets around with a walker and wheelchair. Speaking hand in hand, the couple of a year and a half said they've been leaning on each other through the challenges of addictions and pain. "I need him," Moar said. "I'm happy we get to start a new life." Life at an encampment The pair say their two-month period of homelessness was marked by attacks from people trying to steal their things or take over their camp and by frequent hours-long searches for food, water and supplies. "You're stuck in that survival mode," McCron said. Because of Moar's condition and limited mobility, McCron said those responsibilities often rested with him. "He would pretty much put all the blankets and stuff underneath me, so that way it would be comfortable for my hip," Moar said. "It was pretty hard. It hurt." They also attempted to distance themselves from "hardcore drug addicts," encounters McCron said sometimes led to fights. McCron, though, would have to keep watch throughout the night, saying he sometimes used small amounts of drugs to stay alert and awake. "I didn't really want to use it, but sometimes I had no choice," he said. Winnipeg outreach organization opens new downtown building 8 months ago Before the couple connected with St. Boniface Street Links, they said they had been visited by another organization's outreach team, which dropped off food and supplies and helped them apply for emergency housing. McCron said he and Moar declined to overnight at their shelter due to concerns over drug use there. "What most people don't realize is getting sober is the easy part. Staying sober is the hard part," McCron said. "You're constantly battling cravings. You're constantly battling the thoughts." Counselling and education The pair say they hope their new building will help give them a meaningful opportunity to stave off drug use and provide stability throughout Moar's recovery from surgery. McCron described himself as growing up in a military household marked by alcoholism, and Moar said she was sex trafficked as a teen. They'll have access to counselling and programs, including for addictions and complex trauma, building manager Ainslee Trudeau said. "I'm happy to say that people come in, and we help slowly, baby steps, show them how to be independent, you know, whether that's cooking on a budget, shopping on a budget, whatever the case may be," Trudeau said. A second chance on Fountain Street Michelle Wesley with Street Links said she believes the community-style living is part of what makes the model successful. "It's about, 'How do I live without depending on a substance to help me move forward on a day-to-day basis?'" Wesley said. Moar lived in the building years before it was renovated and run by Street Links. Seeing how it has changed is giving them hope they can, too. "I'm happy we get to start a new life," she said.
CBC
9 hours ago
- CBC
Couple looking forward to new life after trading encampment for supportive housing
A Winnipeg couple experiencing homelessness began a new chapter on Friday, as they moved into transitional housing with hopes of turning a page toward long-term addictions recovery.
